The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
出版年份 2015 全文链接
标题
The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
作者
关键词
-
出版物
CLINICAL INFECTIOUS DISEASES
Volume 61, Issue 3, Pages 403-408
出版商
Oxford University Press (OUP)
发表日期
2015-04-14
DOI
10.1093/cid/civ296
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?
- (2014) Andrew Hill et al. Journal of the International AIDS Society
- Lipid profile changes by high activity anti-retroviral therapy
- (2013) M. Duro et al. CLINICAL BIOCHEMISTRY
- Association of tenofovir exposure with kidney disease risk in HIV infection
- (2012) Rebecca Scherzer et al. AIDS
- Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents
- (2012) Roger Bedimo et al. AIDS
- Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles
- (2012) Georg Behrens et al. ANTIVIRAL THERAPY
- Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
- (2012) José R. Santos et al. PLoS One
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
- (2011) Grace A. McComsey et al. JOURNAL OF INFECTIOUS DISEASES
- A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206
- (2010) Marisa Tungsiripat et al. AIDS
- Rapid Improvement in Fasting Lipids and Hepatic Toxicity After Switching From Didanosine/Lamivudine to Tenofovir/Emtricitabine in Patients With Toxicity Attributable to Didanosine
- (2010) R. Palacios et al. HIV CLINICAL TRIALS
- Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients
- (2010) M. A. Valantin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
- (2009) Roberto Ortiz et al. AIDS
- The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
- (2009) Jose R Arribas et al. AIDS
- Improvements in Subcutaneous Fat, Lipid Profile, and Parameters of Mitochondrial Toxicity in Patients with Peripheral Lipoatrophy When Stavudine is Switched to Tenofovir (LIPOTEST Study)
- (2009) Esteban Ribera et al. HIV CLINICAL TRIALS
- Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients
- (2009) Jose R Arribas et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals
- (2009) Martin Fisher et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy
- (2008) J. Ananworanich et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started